Design of controlled clinical trials for diabetic polyneuropathy

Seminars in Neurology

Volumn 16, Issue 2, 1996, Pages 187-191

  Sima, Anders A F ^a,c   Laudadio, Charles ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trial designs; diabetic neuropathy; drug efficacy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; PLACEBO; PONALRESTAT;

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; HEALTH CARE COST; HUMAN; METHODOLOGY; NEUROLOGIC EXAMINATION; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

EID: 0030479905     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040975     Document Type: Review

References (22)

1. Dyck PJ, Thomas PK, Asbury AK, et al. Diabetic neuropathy. Philadelphia: WB Saunders, 1987
2. Greene DA, Sima AAF, Albers JW, Pfeifer M. Diabetic neuropathy. In Rifkin H, Porte D, eds. Diabetes mellitus. New York: Elsevier, 1989:710-55
3. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral neuropathy. Philadelphia: WB Saunders, 1993:1219-50
4. McNeely J, Pecoraro R. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. Diabetes Care 1995;18:216-9
5. Selby J, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995;18:509-16
6. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Consensus statement. Diabetes 1988;37:1000-4
7. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 1992;15:1080-3
8. Sima AAF, Brown MB, Prashar A, et al. The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral polyneuropathy. Diabetologia 1992;35:560-9
9. Sima AAF, Nathaniel V, Bril V, et al. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988;81.349-64
10. Dyck PJ, Lais A, Karnes JL, et al. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19:425-39
11. Albers JW, Brown MB, Sima AAF, Greene DA, for the Tolrestat Study Group for EDIT (Early Diabetes Intervention Trial): Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the Early Diabetes Intervention Trial (EDIT). Muscle Nerve 1996;19:140-6
12. Peripheral Nerve Society: Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-82
13. Laudadio C. Endpoints and clinical design for evaluating treatments for diabetic neuropathy. In Hotta N, Greene DA, Ward JD, et al, eds. Diabetic neuropathy: new concepts and insights. Amsterdam, Elsevier Science BV, 1995:75-8
14. Laudadio C. Effects of triplicate assessments on power calculations. US-Japan Aldose Reductase Workshop, Kona. 1991 (Abstr)
15. Sima AAF, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548-55
16. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807
17. Dyck PJ, O'Brien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 1989;12:649-52
18. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-87
19. Wei LJ, Lachin JM. Two sample asymptomatically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984;79:653-61
20. Lachin JM. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992;11:1151-70
21. Sima AAF, Prashar A, Zhang W-X, et al. Preventive effect of long term aldose reductase inhibition (Ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic BB-rat. J Clin Invest 1990;85:1410-20
22. Sima AAF, Ristic H, Merry A, et al. The primary preventional and secondary interventative effects of acetyl-L-carnitine on diabetic neuropathy in the BB/W-rat. J Clin Invest 1996;97:1900-7